Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W.
Northend M, et al. Among authors: roddie c.
Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.
Blood Adv. 2022.
PMID: 35020818
Free PMC article.
No abstract available.